vidarabine has been researched along with Genetic Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calvo, K; Cole, K; Cuellar-Rodriguez, J; Freeman, A; Gea-Banacloche, J; Grossman, J; Hakim, F; Hickstein, DD; Holland, SM; Hughes, T; Parta, M; Zerbe, C | 1 |
| Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q | 1 |
| Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C | 1 |
| Bruno, C; Cappelli, B; Castagnola, E; Cuzzubbo, D; Dallorso, S; Dini, G; Faraci, M; Lanino, E; Micalizzi, C; Morreale, G; Rossi, A; Schiaffino, MC | 1 |
1 trial(s) available for vidarabine and Genetic Diseases
| Article | Year |
|---|---|
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; GATA2 Transcription Factor; Genetic Diseases, Inborn; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
3 other study(ies) available for vidarabine and Genetic Diseases
| Article | Year |
|---|---|
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Allogeneic bone marrow transplantation for Pearson's syndrome.
Topics: Antifungal Agents; Antilymphocyte Serum; Antineoplastic Agents; Aspergillosis, Allergic Bronchopulmonary; Base Sequence; Bone Marrow Transplantation; DNA, Mitochondrial; Electron Transport; Female; Genetic Diseases, Inborn; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid; Melphalan; Mitochondrial Diseases; Myeloablative Agonists; Sequence Deletion; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2007 |